Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Greater Acceptance Of Extrapolation & Switching Boosts Biosimilars But Barriers Remain, Says Sandoz Exec

Executive Summary

The biosimilars market is being boosted as physicians become more accepting of biosimilar switching and more willing to prescribe biosimilars on the basis of extrapolation of indications,. However, barriers – including misinformation – remain, as Carol Lynch, president of Sandoz US and chair of the biosimilar medicines group at Medicines for Europe, tells the Pink Sheet.

 

You may also be interested in...



EU Calls For COVID-19 Diagnostic Research Projects

As fears grow that a full-blown COVID-19 pandemic may be on the way, a European public-private consortium is to make available a total of €45m (US$49m) in funding for projects aimed at accelerating the development of diagnostics and therapeutics to help tackle the current outbreak and any future coronavirus threats. 

EU Call For Coronavirus Projects Sparks Big Pharma Interest

Europe’s Innovative Medicines Initiative is calling for R&D projects aimed at tackling the spread of COVID-19, saying that collaborative ventures have the potential to accelerate the development of therapeutics and diagnostics to tackle this and future coronavirus outbreaks.

EU Funding For COVID-19 Drug & Diagnostic Research

Europe’s Innovative Medicines Initiative is to get €90m in funding for programs targeting the coronavirus outbreak.

Topics

Related Companies

UsernamePublicRestriction

Register

PS123111

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel